{"id":970519,"date":"2026-06-04T07:48:25","date_gmt":"2026-06-04T11:48:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/"},"modified":"2026-06-04T07:48:25","modified_gmt":"2026-06-04T11:48:25","slug":"jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/","title":{"rendered":"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <i>Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz&#8217;s unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia<\/i>\n      <\/p>\n<p>\n        <i>For U.S. media and investors only<\/i>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\">DUBLIN<\/span>, <span class=\"legendSpanClass\">June 4, 2026<\/span> \/PRNewswire\/ &#8212; Jazz Pharmaceuticals plc\u00a0(Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40<sup>th<\/sup> annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz&#8217;s continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav<sup>\u00ae<\/sup>\u00a0(calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia.<\/p>\n<p>&#8220;People living with narcolepsy and idiopathic hypersomnia, while profoundly affected by symptoms, face challenges in diagnosis and navigating treatment considerations,&#8221; said\u00a0Jessa Alexander, Ph.D., neuroscience therapeutic area head, global medical and scientific affairs of\u00a0Jazz Pharmaceuticals. &#8220;The research Jazz is unveiling at SLEEP 2026 is rooted in the day-to-day realities of patients, reflecting our commitment to conduct studies that mirror real-world experiences and treatment paradigms. This comprehensive approach allows our research to inform care decisions and address the full complexity of these conditions, spanning the 24-hour burden of sleep inertia, daytime symptoms and sleep as well as the meaningful implications of reducing long-term sodium intake.&#8221;<\/p>\n<p>Key highlights at SLEEP 2026 include:<\/p>\n<ul type=\"disc\">\n<li>An oral presentation featuring a post-hoc analysis of the DUET (Develop hypersomnia\u00a0Understanding by\u00a0Evaluating low-sodium oxybate\u00a0Treatment) study, examining objective and subjective sleep inertia in participants with narcolepsy (type 1 and type 2) taking <i>Xywav<\/i>.<\/li>\n<li>Two poster presentations reporting post-hoc analyses of the DUET study exploring outcomes for idiopathic hypersomnia participants taking <i>Xywav<\/i> treatment, with one evaluating objective and patient-reported sleep inertia and the other exploring outcomes of <i>Xywav <\/i>treatment when stratified by individual ideal sleep duration.<\/li>\n<li>A poster presentation showcasing changes in hypersomnolence among participants with narcolepsy taking <i>Xywav<\/i> dosages &gt;9 grams per night, compared to 9 grams at baseline, in the DUET study. The current recommended dosage of\u00a0<i>Xywav<\/i>\u00a0for adults with narcolepsy is 6-9 grams per night.<\/li>\n<li>Six poster presentations featuring comprehensive findings from the real-world, longitudinal, mixed-methods LYRICAL study, examining the treatment experience and dosing patterns of U.S. adults with idiopathic hypersomnia or narcolepsy taking <i>Xywav<\/i>.<\/li>\n<li>Two poster presentations detailing the development of conceptual disease models of the symptoms and impact of narcolepsy type 1 and narcolepsy type 2, respectively, from the patient perspective to better understand the most bothersome symptoms and meaningful impacts.<\/li>\n<\/ul>\n<p>The\u00a0SLEEP 2026 abstracts\u00a0are\u00a0available\u00a0online\u00a0at: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703638-1&amp;h=270544794&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4437293-1%26h%3D834226093%26u%3Dhttps%253A%252F%252Fwww.sleepmeeting.org%252Fabstract-supplements%252F%26a%3Dsleepmeeting.org%252Fabstract-supplements&amp;a=sleepmeeting.org%2Fabstract-supplements\" target=\"_blank\" rel=\"nofollow\">sleepmeeting.org\/abstract-supplements<\/a>.<\/p>\n<p>The full\u00a0list\u00a0of\u00a0Jazz&#8217;s presentations at SLEEP 2026 is:<\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Presentation Title<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Authors<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Presentation Details<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Improvements in Sleep Inertia With <br \/>Low-Sodium Oxybate Treatment in <br \/>Participants With Narcolepsy Type <br \/>1 and Type 2 in the DUET Study<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Nichols DA, Schneider LD, <br \/>Plante DT, Dai J, Steininger <br \/>TL, Whalen M, Cairns A, <br \/>Ruoff CM, Van Dongen HPA<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Oral and poster <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Oral Session:<\/b> O-23<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Oral Date\/Time:<\/b> June 17, 2026, 4:45-5:00 p.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Session:<\/b> P-35<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Date\/Time:<\/b> June 16, 2026,10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number:<\/b> 339<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Clinical Responders to Low-Sodium <br \/>Oxybate in Narcolepsy and <br \/>Idiopathic Hypersomnia<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Ruoff CM, Sangal RB, <br \/>Nichols DA, Steininger TL, <br \/>Dai J, Vahabzadeh <br \/>S,\u00a0Whalen W, Markt SC, <br \/>Herpel LB,\u00a0Foldvary-<br \/>Schaefer N<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking oral and poster <\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Oral Session:<\/b> LBA-02<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Oral Date\/Time: <\/b>June 16, 2026, 11:00-11:15 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Date\/Time:<\/b> June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number:<\/b> 421<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Estimating the Prevalence of <br \/>Diagnosed Idiopathic Hypersomnia<br \/>in the Pediatric Population: A US <br \/>Claims Analysis<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Gavrielov-Yusim N, Markt <br \/>SC, Nelms J, Bhattacharjee <br \/>R, Maski K<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number:<\/b> 539<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Clinically Relevant Symptoms of <br \/>Narcolepsy and Idiopathic <br \/>Hypersomnia in Patients Initiating <br \/>Low-Sodium Oxybate: Electronic <br \/>Health Record Notes Study<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Markt SC, Whalen M, <br \/>Drachenberg C, Beaty S, <br \/>Alexander JK, Casstevens<br \/>C,\u00a0Fee RM, Russell K, Ortiz <br \/>LE<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number:<\/b> 533<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Improvements in Nighttime Sleep<br \/>Quality and Daytime Sleepiness <br \/>Are Associated With Better Quality <br \/>of Life in Narcolepsy: Findings <br \/>From LYRICAL<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Drachenberg C, Farrell M, <br \/>D&#8217;Souza J, Kim E, Hayes <br \/>C, Zhang D, Lawrence M, <br \/>Graham CA, Whalen M, <br \/>Alexander JK, Beaty S, <br \/>Markt SC,\u00a0Herpel LB<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number:<\/b> 534<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Daytime and Nighttime Symptom<br \/>Improvements Are Associated With <br \/>Better Quality of Life in Idiopathic <br \/>Hypersomnia: Findings From <br \/>LYRICAL<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Drachenberg C, Farrell <br \/>M,\u00a0D&#8217;Souza J, Kim E, <br \/>Hayes C, Zhang D, <br \/>Lawrence M,\u00a0Graham CA, <br \/>Whalen M, Alexander JK, <br \/>Beaty S, Markt SC, Herpel <br \/>LB<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>535<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Changes in Cardiovascular and <br \/>Cardiometabolic Biomarkers <br \/>Following Low-Sodium Oxybate <br \/>Initiation for Narcolepsy or <br \/>Idiopathic Hypersomnia<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Markt SC, Alexander JK, <br \/>Hughes AG, Sachdev A, <br \/>Whalen M, Drachenberg C, <br \/>Beaty S, Dai J, Black J, <br \/>Somers VK<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number:<\/b> 526<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Nocturnal Sleep Features as a <br \/>Candidate Mechanism for <br \/>Improvements in Daytime <br \/>Symptoms in Idiopathic <br \/>Hypersomnia or Narcolepsy<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Cairns A, Plante DT, Ruoff <br \/>CM, Schneider LD, Dai J, <br \/>Nichols DA, Steininger TL, <br \/>Whalen M, Markt SC, <br \/>Bogan RK, Dauvilliers Y, <br \/>Mignot E<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number:<\/b> 537<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Nocturnal Sleep Features as <br \/>Candidates for Evaluating Disease <br \/>Specific Improvements in Idiopathic <br \/>Hypersomnia or Narcolepsy<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Cairns A, Plante DT, Ruoff <br \/>CM, Schneider LD, Dai J, <br \/>Nichols DA, Steininger TL, <br \/>Whalen M, Markt SC, <br \/>Bogan RK, Dauvilliers Y, <br \/>Mignot E<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>536<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Changes in Patient-Reported <br \/>Symptoms After Switching From <br \/>High- to Low-Sodium Oxybate in <br \/>Participants With Narcolepsy in the <br \/>XYLO Study<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Somers VK, Dauvilliers Y, <br \/>Nichols DA, Markt SC, <br \/>Baranak C, Dai J, Measey <br \/>TJ, Whalen M, White WB<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>527<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Individualized Dosing and Drug <br \/>Utilization of Low-Sodium Oxybate <br \/>in Narcolepsy and Idiopathic <br \/>Hypersomnia: Results from Post-<br \/>Marketing Data<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Gavrielov-Yusim N, Nelms <br \/>J, Dai J, Balmuri P, <br \/>Saumweber A, Singer D, <br \/>Skobieranda F, Patodiya V, <br \/>Markt S<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>529<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Individualized Dosing of Low-<br \/>Sodium Oxybate in Patients with <br \/>Narcolepsy or Idiopathic <br \/>Hypersomnia<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Foldvary-Schaefer N, <br \/>Meskill GJ, Nichols DA, <br \/>Steininger TL, Dai J, <br \/>Measey T, Whalen M, <br \/>Cairns A, Schneider LD, <br \/>Bogan RK<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Late-breaking poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session:<\/b> P-41<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b>\u00a0June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>528<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Improvements in Sleep Inertia With<br \/>Low-Sodium Oxybate Treatment in <br \/>Participants With Idiopathic<br \/>Hypersomnia in the DUET Study<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Nichols DA, Schneider LD, <br \/>Ruoff CM, Dai J, Steininger <br \/>TL, Whalen M, Cairns A, <br \/>Plante DT, Van Dongen <br \/>HPA<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-35<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>338<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Patient-Reported Improvement in <br \/>Hypersomnolence Measures in <br \/>Participants With Narcolepsy <br \/>Taking &gt;9 Gram Dosage of Low-<br \/>Sodium Oxybate in the DUET Study<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Bogan RK, Ruoff CM, <br \/>Plante DT, Nichols DA, <br \/>Steininger TL, Dai J, <br \/>Measey TJ, Whalen M, <br \/>Cairns A, Schneider LD, <br \/>Simmons JH<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-35<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>331<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Effectiveness and Safety of Low-<br \/>Sodium Oxybate by Patient-<br \/>Reported Long Sleep Need in <br \/>DUET Study Participants With <br \/>Idiopathic Hypersomnia<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Plante DT, Ruoff CM, <br \/>Schneider LD, Nichols DA, <br \/>Steininger TL, Cairns A, Dai <br \/>J, Whalen M, Dauvilliers Y<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-35<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b> June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>325<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">A Conceptual Disease Model of the <br \/>Symptoms and Impacts of <br \/>Narcolepsy Type 1 From the <br \/>Patient Perspective<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Casstevens C, Foldvary-<br \/>Schaefer N, Maski K, <br \/>Plante DT, Farrell M, <br \/>Graham CA, Mobley C, Kim<br \/>E, Wraight M, Black J, <br \/>Steinerman JR, Ortiz LE<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-34<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b> June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>302<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">A Conceptual Disease Model of the <br \/>Symptoms and Impacts of <br \/>Narcolepsy Type 2 From the <br \/>Patient Perspective<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Casstevens C, Maski K,<br \/>Foldvary-Schaefer N, Ortiz<br \/>LE, Farrell M, Graham CA, <br \/>Mobley C, Kim E, Wraight <br \/>M, Black J, Steinerman JR, <br \/>Plante DT<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-34<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>303<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Effectiveness and Satisfaction With <br \/>Low-Sodium Oxybate As Described <br \/>by Adults Living With Narcolepsy: <br \/>LYRICAL Survey &amp; Interview <br \/>Findings<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Drachenberg C, Farrell M, <br \/>D&#8217;Souza J, Kim E, <br \/>Lawrence M, Graham CA, <br \/>Whalen M, Alexander JK, <br \/>Beaty S, Markt SC, Herpel<br \/>LB<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-38<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>359<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Effectiveness and Satisfaction With<br \/>Low-Sodium Oxybate As Described <br \/>by Adults Living With Idiopathic <br \/>Hypersomnia: LYRICAL Survey &amp; <br \/>Interview Findings<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Drachenberg C, Farrell M, <br \/>D&#8217;Souza J, Kim E, <br \/>Lawrence M, Graham CA, <br \/>Whalen M, Alexander JK, <br \/>Beaty S, Markt SC, Herpel <br \/>LB<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-38<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>360<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Individualized Dosing With Low-<br \/>Sodium Oxybate in Narcolepsy: <br \/>Patient Voices From LYRICAL<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Drachenberg C, Farrell M, <br \/>D&#8217;Souza J, Kim E, <br \/>Lawrence M, Graham CA, <br \/>Whalen M, Alexander JK, <br \/>Beaty S, Markt SC, Herpel <br \/>LB<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-38<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time:<\/b> June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>362<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Individualized Dosing With Low-<br \/>Sodium Oxybate in Idiopathic <br \/>Hypersomnia: Patient Voices From<br \/>LYRICAL<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\">Drachenberg C, Farrell M, <br \/>D&#8217;Souza J, Kim E, <br \/>Lawrence M, Graham CA,<br \/>Whalen M, Alexander JK, <br \/>Beaty S, Markt SC, Herpel <br \/>LB<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" nowrap=\"nowrap\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Type:<\/b> Poster<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Session: <\/b>P-38<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Date\/Time: <\/b>June 16, 2026, 10:00-11:45 a.m. ET<\/span>\n              <\/p>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Poster Board Number: <\/b>361<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\n        <b>About Xywav<\/b><br \/>\n        <b><br \/>\n          <sup>\u00ae<\/sup><br \/>\n        <\/b>\u00a0<b>(calcium, magnesium, potassium, and sodium oxybates) oral solution<\/b><br \/><i>Xywav<\/i>\u00a0is the only low-sodium oxybate approved by the\u00a0U.S. Food and Drug Administration\u00a0(FDA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. The FDA recognized seven years of Orphan Drug Exclusivity for\u00a0<i>Xywav<\/i>\u00a0for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. The Office of Orphan Product Development (OOPD) at the FDA also published its summary of clinical superiority findings for\u00a0<i>Xywav<\/i>\u00a0for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy by means of greater cardiovascular safety compared to Xyrem<sup>\u00ae<\/sup>\u00a0(sodium oxybate) oral solution. The decision of the OOPD is based on the FDA findings that\u00a0<i>Xywav<\/i>\u00a0provides a greatly reduced chronic sodium burden compared to\u00a0<i>Xyrem<\/i>.\u00a0<i>Xywav<\/i>\u00a0has 131 mg of sodium at the maximum recommended nightly dose\u00a0whereas other high sodium oxybates have 1640 mg at the equivalent dose.\u00a0<i>Xywav<\/i>\u00a0is comprised of a unique composition of cations resulting in 92% less sodium, or a reduction of approximately 1,000 to 1,500 mg\/night at the recommended dose range of 6 g to 9 g\/night.\u00a0<i>Xywav<\/i>\u00a0is the only oxybate therapy that does not carry a warning in the label related to use in patients sensitive to high sodium intake.<\/p>\n<p>\n        <i>Xywav<\/i>\u00a0is also the first and only\u00a0FDA-approved treatment option for idiopathic hypersomnia in adults. The FDA recognized seven years of Orphan Drug Exclusivity for\u00a0<i>Xywav<\/i>\u00a0for the treatment of idiopathic hypersomnia in adults.\u00a0<i>Xywav<\/i>\u00a0is the only FDA-approved treatment studied across the multiple symptoms of idiopathic hypersomnia, such as EDS, sleep inertia (severe grogginess or confusion when waking up), long sleep duration and cognitive impairment.\u00a0<i>Xywav<\/i>\u00a0can be administered as a twice- or once-nightly regimen for the treatment of idiopathic hypersomnia in adults.<\/p>\n<p>The exact mechanism of action of\u00a0<i>Xywav<\/i>\u00a0in the treatment of adults with idiopathic hypersomnia and of cataplexy and EDS in narcolepsy is unknown. It is hypothesized that the therapeutic effects of\u00a0<i>Xywav<\/i>\u00a0are mediated through GABA<sub>B<\/sub>\u00a0actions during sleep at noradrenergic and dopaminergic neurons, as well as thalamocortical neurons.<sup>1<\/sup>\u00a0The\u00a0U.S.\u00a0Drug Enforcement Agency\u00a0(DEA) has designated\u00a0<i>Xywav<\/i>\u00a0as a Schedule III medicine. The DEA defines Schedule III drugs, substances, or chemicals as drugs with a moderate to low potential for physical and psychological dependence.<sup>1,2<\/sup>\u00a0Because of the risks of central nervous system (CNS) depression and abuse and misuse,\u00a0<i>Xywav<\/i>\u00a0is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS.<\/p>\n<p>\n        <b>Important Safety Information for Xywav<\/b>\n      <\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prncbts prnbrbrs prnbbbs prnbsbls\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.<\/b><br \/>\n                <\/span>\n              <\/p>\n<ul type=\"disc\">\n<li class=\"prnews_li\">\n                  <span class=\"prnews_span\"><br \/>\n                    <b><br \/>\n                      <u>Central Nervous System Depression<\/u><br \/>\n                    <\/b><br \/>\n                  <\/span><br \/>\n                  <br \/>\n                  <span class=\"prnews_span\"><br \/>\n                    <b>XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses. Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving CNS stimulants.<\/b><br \/>\n                  <\/span><br \/>\n                  <br \/>\n                  <span class=\"prnews_span\">\u00a0<\/span>\n                <\/li>\n<li class=\"prnews_li\">\n                  <span class=\"prnews_span\"><br \/>\n                    <b><br \/>\n                      <u>Abuse and Misuse<\/u><br \/>\n                    <\/b><br \/>\n                  <\/span><br \/>\n                  <br \/>\n                  <span class=\"prnews_span\"><br \/>\n                    <b>The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.<\/b><br \/>\n                  <\/span>\n                <\/li>\n<\/ul>\n<p class=\"prnml4\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Because of the risks of\u00a0CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a REMS called the XYWAV and XYREM REMS.<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\n        <b><br \/>\n          <u>Contraindications<\/u><br \/>\n        <\/b><br \/>\n        <br \/>XYWAV\u00a0is\u00a0contraindicated<\/p>\n<ul type=\"disc\">\n<li>in combination with sedative hypnotics or alcohol and<\/li>\n<li>in patients with\u00a0succinic\u00a0semialdehyde\u00a0dehydrogenase\u00a0deficiency.<\/li>\n<\/ul>\n<p>\n        <b><br \/>\n          <u>Warnings and Precautions<\/u><br \/>\n        <\/b><br \/>\n        <br \/>\n        <b>Central Nervous System Depression<br \/><\/b>The concurrent use of XYWAV with other CNS depressants, including but not limited to opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, sedating anti-epileptic drugs, general anesthetics, muscle relaxants, and\/or illicit CNS depressants, may increase the risk of respiratory depression, hypotension, profound sedation, syncope, and death. If use of these CNS depressants in combination with XYWAV is required, dose reduction or discontinuation of one or more CNS depressants (including XYWAV) should be considered. In addition, if short-term use of an opioid (e.g., post- or perioperative) is required, interruption of treatment with XYWAV should be considered.<\/p>\n<p>After\u00a0first initiating treatment\u00a0and until certain that\u00a0XYWAV\u00a0does not affect\u00a0them\u00a0adversely (e.g., impair\u00a0judgment, thinking,\u00a0or motor skills), caution\u00a0patients against\u00a0hazardous\u00a0activities\u00a0requiring complete\u00a0mental alertness\u00a0or motor\u00a0coordination\u00a0such as operating\u00a0hazardous\u00a0machinery, including\u00a0automobiles\u00a0or airplanes. Also caution patients against these hazardous activities for at least 6 hours after taking\u00a0XYWAV. Patients\u00a0should be queried\u00a0about CNS depression-related events\u00a0upon initiation\u00a0of XYWAV\u00a0therapy\u00a0and\u00a0periodically\u00a0thereafter.<\/p>\n<p>\n        <b>Abuse and Misuse<\/b><br \/>\n        <br \/>XYWAV is a Schedule Ill controlled substance. The active moiety of XYWAV is oxybate, also known as\u00a0GHB, a Schedule\u00a0I controlled substance. Abuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death. The rapid onset of sedation, coupled with the amnestic features of\u00a0GHB particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g., assault victim). Physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely.<\/p>\n<p>\n        <b>XYWAV<\/b>\u00a0<b>and<\/b>\u00a0<b>XYREM<\/b>\u00a0<b>REMS<\/b><br \/>Because of the risks of central nervous system depression and abuse and misuse,\u00a0XYWAV is available only through a restricted distribution program called the XYWAV and XYREM REMS.<\/p>\n<p>Notable\u00a0requirements\u00a0of\u00a0the\u00a0XYWAV\u00a0and\u00a0XYREM\u00a0REMS\u00a0include the\u00a0following:<\/p>\n<ul type=\"disc\">\n<li>Healthcare Providers who prescribe\u00a0XYWAV\u00a0are\u00a0specially certified<\/li>\n<li>XYWAV\u00a0will\u00a0be\u00a0dispensed\u00a0only\u00a0by\u00a0the\u00a0central\u00a0pharmacy that\u00a0is\u00a0specially\u00a0certified<\/li>\n<li>XYWAV\u00a0will be dispensed\u00a0and shipped\u00a0only to patients\u00a0who are enrolled in the XYWAV and\u00a0XYREM\u00a0REMS\u00a0with\u00a0documentation\u00a0of\u00a0safe\u00a0use<\/li>\n<\/ul>\n<p>Further\u00a0information\u00a0is available\u00a0at\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703638-1&amp;h=3628093508&amp;u=https%3A%2F%2Fwww.xywavxyremrems.com%2F&amp;a=www.XYWAVXYREMREMS.com\" target=\"_blank\" rel=\"nofollow\">www.XYWAVXYREMREMS.com<\/a>\u00a0or\u00a01-866-997-3688.<\/p>\n<p>\n        <b>Respiratory Depression and Sleep-Disordered Breathing<\/b><br \/>\n        <br \/>XYWAV may impair respiratory drive, especially in patients with compromised respiratory function. In\u00a0overdoses\u00a0of oxybate\u00a0and\u00a0with illicit\u00a0use of GHB, life-threatening respiratory depression\u00a0has been\u00a0reported. Increased apnea and reduced oxygenation may occur with XYWAV administration in adult and pediatric patients. A significant increase in the number of central apneas and clinically significant oxygen desaturation\u00a0may occur\u00a0in patients with obstructive\u00a0sleep apnea\u00a0treated with XYWAV. Prescribers should be aware that sleep-related breathing disorders tend to be more prevalent in obese patients, in men, in postmenopausal women not on hormone replacement therapy, and among patients with narcolepsy.<\/p>\n<p>\n        <b>Depression and<\/b>\u00a0<b>Suicidality<\/b><br \/>In Study 1, the randomized-withdrawal clinical trial in adult patients with narcolepsy (n=201), depression\u00a0and depressed mood were reported in 3% and 4%, respectively,\u00a0of patients treated with XYWAV. Two patients\u00a0(1%)\u00a0discontinued\u00a0XYWAV because\u00a0of depression. In most cases, no change in XYWAV treatment was required.\u00a0<\/p>\n<p>In Study 2, the randomized-withdrawal clinical trial in adult patients with idiopathic hypersomnia (n=154), depression and depressed mood were reported in 1% and 3%, respectively, of patients treated with XYWAV. All patients continued XYWAV treatment.<\/p>\n<p>Two suicides and two attempted suicides occurred in adult clinical trials with oxybate (same active moiety as XYWAV). One patient experienced suicidal ideation and two patients reported depression in a pediatric clinical trial with oxybate. These events occurred in patients with and without previous histories of depressive disorders. The emergence\u00a0of\u00a0depression\u00a0in patients treated\u00a0with XYWAV requires careful and immediate\u00a0evaluation. Monitor patients for the emergence of increased\u00a0depressive\u00a0symptoms and\/or suicidality\u00a0while\u00a0taking\u00a0XYWAV.<\/p>\n<p>\n        <b>Other Behavioral or Psychiatric Adverse Reactions<\/b><br \/>\n        <br \/>In\u00a0Study 1,\u00a0confusion and anxiety\u00a0occurred\u00a0in\u00a01% and 5% of\u00a0patients with narcolepsy\u00a0treated\u00a0with XYWAV, respectively. One patient\u00a0experienced\u00a0visual\u00a0hallucinations and confusion\u00a0after\u00a0ingesting approximately\u00a09\u00a0grams\u00a0of XYWAV.<\/p>\n<p>In Study 2, confusion and anxiety occurred in 3% and 16% of patients with idiopathic hypersomnia, respectively.\u00a0One patient experienced visual hallucinations, which led to discontinuation of XYWAV.\u00a0<\/p>\n<p>Other\u00a0neuropsychiatric\u00a0reactions reported\u00a0with oxybate\u00a0(same\u00a0active\u00a0moiety as XYWAV)\u00a0in adult or pediatric clinical\u00a0trials\u00a0and in the postmarketing setting include hallucinations, paranoia, psychosis, aggression, agitation, confusion and anxiety. The emergence or increase in the occurrence of behavioral or psychiatric events in patients taking XYWAV should\u00a0be\u00a0carefully monitored.<\/p>\n<p>\n        <b>Parasomnias<\/b><br \/>\n        <br \/>Parasomnias\u00a0can\u00a0occur\u00a0in\u00a0patients\u00a0taking\u00a0XYWAV.<\/p>\n<p>In Study 1 and Study 2,\u00a0parasomnias, including sleepwalking, were reported in 6% and 5% of adult patients treated with\u00a0XYWAV, respectively.\u00a0<\/p>\n<p>In\u00a0a\u00a0clinical trial\u00a0of\u00a0XYREM\u00a0(same\u00a0active moiety\u00a0as\u00a0XYWAV) in adult patients with narcolepsy, five instances of sleepwalking with potential injury or significant injury were reported. Parasomnias, including sleepwalking, have been reported in a pediatric clinical trial with sodium oxybate\u00a0(same\u00a0active\u00a0moiety\u00a0as\u00a0XYWAV) and\u00a0in\u00a0postmarketing\u00a0experience\u00a0with\u00a0sodium\u00a0oxybate.<\/p>\n<p>Episodes\u00a0of\u00a0sleepwalking\u00a0should\u00a0be\u00a0fully\u00a0evaluated\u00a0and\u00a0appropriate\u00a0interventions\u00a0considered.<\/p>\n<p>\n        <b><br \/>\n          <u>Most Common Adverse Reactions<\/u><br \/>\n        <\/b><br \/>\n        <br \/>The\u00a0most\u00a0common adverse\u00a0reactions (occurring in \u22655% of XYWAV-treated patients in adult clinical trials in either narcolepsy or IH) were nausea, headache,\u00a0dizziness, anxiety, insomnia, decreased appetite,\u00a0hyperhidrosis, vomiting, diarrhea, dry mouth, parasomnia, somnolence, fatigue, and tremor.\u00a0<\/p>\n<p>In\u00a0the\u00a0pediatric clinical\u00a0trial\u00a0with\u00a0XYREM\u00a0(same\u00a0active\u00a0moiety\u00a0as\u00a0XYWAV) that included pediatric patients 7 to 17 years of age with narcolepsy, the most common adverse reactions (\u22655%) were nausea (20%), enuresis (19%), vomiting (18%), headache (17%), weight decreased (13%), decreased appetite (9%), dizziness (8%), and sleepwalking (6%). The overall adverse reaction profile of\u00a0XYREM in the pediatric\u00a0clinical trial was similar to that seen in the adult clinical trial\u00a0program. The safety profile in pediatric patients\u00a0with XYWAV is expected\u00a0to be similar\u00a0to that\u00a0of adult\u00a0patients treated\u00a0with XYWAV and to that of pediatric patients treated with XYREM.<\/p>\n<p>\n        <b><br \/>\n          <u>Additional Adverse Reactions<\/u><br \/>\n        <\/b><br \/>\n        <br \/>Adverse reactions that occurred in\u00a02-&lt;5% of adult patients treated with XYWAV in the Open Label Titration and Stable Dose Periods of the randomized-withdrawal study in adult patients with narcolepsy with cataplexy (Study 1) were fatigue, dry mouth, depressed mood, enuresis, irritability, paresthesia, depression, tremor, somnolence, and muscle spasms. Adverse reactions occurring in 2-&lt;5% of patients treated with\u00a0XYWAV in the IH study include balance disorder, muscle spasms, fall, paresthesia,\u00a0snoring, weight decreased, bruxism, confusional state, depressed mood, feeling drunk, and irritability.<\/p>\n<p>Adverse reactions that occurred in\u00a0\u22652% of patients in clinical studies with oxybate (but not in\u00a0Study\u00a01)\u00a0and\u00a0which\u00a0may\u00a0be\u00a0relevant for\u00a0XYWAV,\u00a0were\u00a0pain,\u00a0feeling drunk,\u00a0pain\u00a0in\u00a0extremity,\u00a0cataplexy, disturbance\u00a0in\u00a0attention,\u00a0sleep\u00a0paralysis,\u00a0and\u00a0disorientation.<\/p>\n<p>Discontinuation: In Study 1, 9 of 201 patients (4%) reported adverse reactions that led to withdrawal from the study (anxiety, decreased appetite, depressed mood, depression, fatigue, headache, irritability, nausea, pain in extremity, parasomnia, somnolence, and vomiting). The most common adverse reaction leading to discontinuation was nausea (1.5%). In Study 2, 17 of 154 (11%) patients across all study periods (excluding placebo during the DB\u00a0RWP) (up to 42\u00a0weeks) reported adverse reactions that led to withdrawal from the study (anxiety, nausea, insomnia, vomiting, fatigue, feeling abnormal, fall, decreased appetite, dizziness, paresthesia, tremor, parasomnia, confusional state, hallucination visual, and irritability). The most common adverse reaction leading to discontinuation was anxiety (3.2%). In Study 1 and Study 2, the majority of adverse reactions leading to discontinuation began during the first few weeks of treatment.<\/p>\n<p>In the pediatric clinical trial with XYREM (same active moiety as XYWAV), 7 of 104 patients reported adverse reactions that led to withdrawal from the study (hallucination, tactile; suicidal ideation; weight decreased; sleep apnea syndrome; affect lability; anger, anxiety, depression; and headache).<\/p>\n<p>\n        <b><br \/>\n          <u>Drug Interactions<\/u><br \/>\n        <\/b><br \/>\n        <br \/>XYWAV is contraindicated in combination with alcohol or sedative hypnotics. Use of other CNS depressants\u00a0may\u00a0potentiate\u00a0the\u00a0CNS-depressant\u00a0effects of\u00a0XYWAV.<\/p>\n<p>Concomitant\u00a0use of sodium\u00a0oxybate with divalproex\u00a0sodium\u00a0results in an increase in systemic\u00a0exposure to\u00a0GHB, which was shown to cause a greater impairment on some tests of attention and working memory in a clinical study. A similar increase in exposure is expected with concomitant use of\u00a0XYWAV and divalproex\u00a0sodium; therefore, an initial dose reduction of XYWAV is recommended when used concomitantly with\u00a0divalproex\u00a0sodium. Prescribers\u00a0are advised\u00a0to monitor\u00a0patient\u00a0response closely and adjust dose accordingly\u00a0if\u00a0concomitant\u00a0use\u00a0of\u00a0XYWAV\u00a0and\u00a0divalproex\u00a0sodium\u00a0is\u00a0warranted.<\/p>\n<p>\n        <b><br \/>\n          <u>Pregnancy and Lactation<\/u><br \/>\n        <\/b><br \/>\n        <br \/>There are no adequate data on the developmental risk associated with the use of XYWAV or sodium\u00a0oxybate\u00a0in pregnant women. XYWAV should be used during pregnancy\u00a0only if the potential benefit\u00a0justifies\u00a0the\u00a0potential\u00a0risk\u00a0to\u00a0the\u00a0fetus.\u00a0GHB is excreted in human milk after oral administration of sodium\u00a0oxybate.\u00a0There is insufficient\u00a0information\u00a0on the risk to a breastfed infant, and there is insufficient\u00a0information\u00a0on milk\u00a0production\u00a0in nursing\u00a0mothers.\u00a0The\u00a0developmental\u00a0and\u00a0health\u00a0benefits of\u00a0breastfeeding should be\u00a0considered along with the mother&#8217;s clinical need for XYWAV and any potential adverse effects on the breastfed infant\u00a0from XYWAV\u00a0or\u00a0from\u00a0the\u00a0underlying maternal\u00a0condition.<\/p>\n<p>\n        <b><br \/>\n          <u>Pediatric Use<\/u><br \/>\n        <\/b><br \/>\n        <br \/>The\u00a0safety and\u00a0effectiveness\u00a0of\u00a0XYWAV for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients 7 years of age and older with narcolepsy have been established. XYWAV\u00a0has not been studied in a pediatric clinical trial for narcolepsy or\u00a0IH. Use of\u00a0XYWAV in pediatric patients 7 years of age and older with narcolepsy is supported by evidence from an adequate and well-controlled study of sodium oxybate in pediatric patients 7 to 17 years of age, a study in adults showing a treatment effect of XYWAV similar\u00a0to\u00a0that\u00a0observed\u00a0with\u00a0sodium\u00a0oxybate,\u00a0pharmacokinetic data\u00a0of sodium oxybate from adult and pediatric patients, and pharmacokinetic data\u00a0of XYWAV\u00a0from\u00a0healthy\u00a0adult\u00a0volunteers.<\/p>\n<p>Safety\u00a0and\u00a0effectiveness\u00a0of\u00a0XYWAV\u00a0in\u00a0pediatric\u00a0patients below\u00a0the\u00a0age\u00a0of\u00a07\u00a0years\u00a0with narcolepsy have\u00a0not\u00a0been\u00a0established.<\/p>\n<p>Safety and effectiveness of XYWAV for the treatment of idiopathic hypersomnia in pediatric patients have not been established.<\/p>\n<p>\n        <b><br \/>\n          <u>Geriatric Use<\/u><br \/>\n        <\/b><br \/>\n        <br \/>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the\u00a0dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of\u00a0concomitant\u00a0disease or\u00a0other\u00a0drug\u00a0therapy.<\/p>\n<p>\n        <b><br \/>\n          <u>Hepatic Impairment<\/u><br \/>\n        <\/b><br \/>\n        <br \/>The\u00a0starting\u00a0dose\u00a0of\u00a0XYWAV\u00a0should\u00a0be\u00a0reduced\u00a0in\u00a0patients\u00a0with\u00a0liver\u00a0impairment.<\/p>\n<p>\n        <b>Dosage Modification in Patients with Hepatic Impairment:<\/b>\u00a0The recommended starting dosage in patients with hepatic impairment is one-half of the original dosage per night, administered orally, divided into two doses.<\/p>\n<p>\n        <b><br \/>\n          <u>Dependence and Tolerance<\/u><br \/>\n        <\/b><br \/>\n        <br \/>There\u00a0have\u00a0been\u00a0case\u00a0reports\u00a0of\u00a0withdrawal,\u00a0ranging\u00a0from\u00a0mild\u00a0to\u00a0severe,\u00a0following\u00a0discontinuation\u00a0of\u00a0illicit use of GHB\u00a0at frequent\u00a0repeated\u00a0doses\u00a0(18\u00a0g to 250 g per day)\u00a0in excess\u00a0of the recommended\u00a0dosage range. Signs and symptoms\u00a0of GHB withdrawal following abrupt discontinuation included insomnia, restlessness, anxiety, psychosis, lethargy, nausea, tremor, sweating, muscle cramps, tachycardia, headache, dizziness, rebound fatigue and sleepiness, confusion, and, particularly in the case of severe withdrawal, visual hallucinations, agitation, and delirium. These symptoms generally abated in 3 to 14 days. In cases of severe withdrawal, hospitalization may be required.<\/p>\n<p>In the clinical trial experience\u00a0with\u00a0XYREM in narcolepsy\/cataplexy patients at recommended doses, two patients reported anxiety and one reported insomnia following abrupt discontinuation at the termination of the clinical trial; in the two patients with anxiety, the frequency of cataplexy had increased markedly at the same time. In the\u00a0XYWAV clinical trial in adult narcolepsy\/cataplexy patients at recommended doses,\u00a0one patient\u00a0reported insomnia\u00a0following\u00a0abrupt\u00a0discontinuation\u00a0of\u00a0XYWAV. In the XYWAV clinical trial in adult idiopathic hypersomnia patients at recommended doses, six patients reported insomnia, two patients reported early insomnia, and one patient reported visual and auditory hallucinations following abrupt discontinuation of XYWAV<i>.<\/i><\/p>\n<p>Tolerance to XYWAV has not been systematically studied in controlled clinical trials. There have been\u00a0some case reports of symptoms of tolerance developing after illicit use at dosages far in excess of the recommended XYWAV dosage regimen.<\/p>\n<p>Please see full Prescribing Information, including BOXED Warning here: <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703638-1&amp;h=2825400565&amp;u=https%3A%2F%2Fpp.jazzpharma.com%2Fpi%2Fxywav.en.USPI.pdf&amp;a=https%3A%2F%2Fpp.jazzpharma.com%2Fpi%2Fxywav.en.USPI.pdf\" target=\"_blank\" rel=\"nofollow\">https:\/\/pp.jazzpharma.com\/pi\/xywav.en.USPI.pdf<\/a><\/p>\n<p>\n        <b>About<\/b>\u00a0<b>Jazz Pharmaceuticals<\/b><br \/>Jazz Pharmaceuticals plc\u00a0(NASDAQ: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease \u2014 often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in\u00a0Dublin, Ireland\u00a0with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703638-1&amp;h=4235976877&amp;u=https%3A%2F%2Fwww.jazzpharmaceuticals.com%2F&amp;a=www.jazzpharmaceuticals.com\" target=\"_blank\" rel=\"nofollow\">www.jazzpharmaceuticals.com<\/a>\u00a0for more information.<\/p>\n<p>\n        <b>References<\/b>:<\/p>\n<ol type=\"1\">\n<li>Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution. Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.<\/li>\n<li>United States Drug Enforcement Agency. Drug Scheduling. <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4703638-1&amp;h=3752435686&amp;u=https%3A%2F%2Fwww.dea.gov%2Fdrug-information%2Fdrug-scheduling&amp;a=https%3A%2F%2Fwww.dea.gov%2Fdrug-information%2Fdrug-scheduling\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.dea.gov\/drug-information\/drug-scheduling<\/a>. Accessed May 2026.<\/li>\n<\/ol>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <b>Media:<\/b><br \/>\n        <br \/>\n        <a href=\"mailto:CorporateAffairsMediaInfo@jazzpharma.com\" target=\"_blank\" rel=\"nofollow\">CorporateAffairsMediaInfo@jazzpharma.com<\/a><br \/>\n        <br \/>Ireland +353 1 637 2141<br \/>U.S. +1 215 867 4948<\/p>\n<p>\n        <b>Investors:<\/b><br \/>\n        <br \/>\n        <a href=\"mailto:InvestorInfo@jazzpharma.com\" target=\"_blank\" rel=\"nofollow\">InvestorInfo@jazzpharma.com<\/a><br \/>\n        <br \/>Ireland +353 1 634 3211<br \/>U.S. +1 650 496 2717<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder4421\">\n<p>\n          <img decoding=\"async\" src=\"https:\/\/mmx.prnewswire.com\/media\/MS378420\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004\" title=\"Jazz Pharmaceuticals Logo (PRNewsFoto\/Jazz Pharmaceuticals plc) (PRNewsFoto\/Jazz Pharmaceuticals plc)\" alt=\"Jazz Pharmaceuticals Logo (PRNewsFoto\/Jazz Pharmaceuticals plc) (PRNewsFoto\/Jazz Pharmaceuticals plc)\" \/>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=SF75470&amp;sd=2026-06-04\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with-narcolepsy-and-idiopathic-hypersomn-302790801.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with-narcolepsy-and-idiopathic-hypersomn-302790801.html<\/a><\/p>\n<p>SOURCE Jazz Pharmaceuticals plc<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF75470&amp;Transmission_Id=202606040745PR_NEWS_USPR_____SF75470&amp;DateId=20260604\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz&#8217;s unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 \/PRNewswire\/ &#8212; Jazz Pharmaceuticals plc\u00a0(Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz&#8217;s continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav\u00ae\u00a0(calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia. &#8220;People living with narcolepsy and idiopathic hypersomnia, while &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-970519","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz&#8217;s unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 \/PRNewswire\/ &#8212; Jazz Pharmaceuticals plc\u00a0(Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz&#8217;s continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav\u00ae\u00a0(calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia. &#8220;People living with narcolepsy and idiopathic hypersomnia, while &hellip; Continue reading &quot;Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-04T11:48:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS378420\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"21 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia\",\"datePublished\":\"2026-06-04T11:48:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/\"},\"wordCount\":4291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS378420\\\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/\",\"name\":\"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS378420\\\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004\",\"datePublished\":\"2026-06-04T11:48:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS378420\\\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS378420\\\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/","og_locale":"en_US","og_type":"article","og_title":"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - Market Newsdesk","og_description":"PR Newswire Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz&#8217;s unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN, June 4, 2026 \/PRNewswire\/ &#8212; Jazz Pharmaceuticals plc\u00a0(Nasdaq: JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz&#8217;s continued focus on advancing treatment for rare and difficult-to-treat sleep disorders with new clinical research and real-world evidence evaluating Xywav\u00ae\u00a0(calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia. &#8220;People living with narcolepsy and idiopathic hypersomnia, while &hellip; Continue reading \"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-04T11:48:25+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS378420\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"21 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia","datePublished":"2026-06-04T11:48:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/"},"wordCount":4291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS378420\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/","name":"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS378420\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004","datePublished":"2026-06-04T11:48:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS378420\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS378420\/Jazz_Pharmaceuticals_New_Logo.jpg?id=OA2657004"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jazz-pharmaceuticals-to-present-comprehensive-data-at-sleep-2026-highlighting-broad-treatment-effects-of-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-for-people-with\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=970519"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/970519\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=970519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=970519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=970519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}